Two problems have been associated with the clinical use of anti-HBcAg IgM determinations. Rheumatoid factor (RF) and other similar substances may seriously interfere with any solid-phase assay for IgM antibodies (1, 6). The frequent occurrence of low levels of anti-HBcAg IgM for prolonged periods after acute hepatitis B has been reported (4). This has been associated with the use of core antigen from human liver. In fact, increased levels of different autoantibodies against liver components, as well as increased levels of RF, have been observed in hepatitis B (2, 4).
The presence of immunoglobulin M (IgM) antibodies against hepatitis B core antigen (HBcAg) is an indication of acute or recent hepatitis B virus infection (2, 4, 7, 8, 10) . The test for anti-HBcAg IgM is particularly important in the absence of other hepatitis B markers and in cases in which patients are chronic carriers of hepatitis B surface antigen (HBsAg) without clinical symptoms.
Two problems have been associated with the clinical use of anti-HBcAg IgM determinations. Rheumatoid factor (RF) and other similar substances may seriously interfere with any solid-phase assay for IgM antibodies (1, 6) . The frequent occurrence of low levels of anti-HBcAg IgM for prolonged periods after acute hepatitis B has been reported (4) . This has been associated with the use of core antigen from human liver. In fact, increased levels of different autoantibodies against liver components, as well as increased levels of RF, have been observed in hepatitis B (2, 4) .
We have developed a new modification of enzyme immunoassay for the determination of anti-HBcAg IgM which seems to be able to avoid the undesired effect of RF and other autoantibodies. The core antigen used in this modification was a purified product from Escherichia coli produced by recombinant DNA technology and should be naturally free from contaminating human tissue components. The present modification was a capture assay with anti-human . on the solid phase. Biotin labeling of the core antigen was used, and labeled antigen was detected by an avidin-biotinperoxidase complex (ABC). In this paper, the optimal conditions for the assay and some clinical experiences with its use are described.
MATERIALS AND METHODS Antigen. HBcAg was produced in E. coli (9) RF-positive sera. Ten anti-HBcAg-positive but HBsAgnegative sera which were positive for RF when tested by a latex agglutination test (Rapitex-RF; Behringwerke) were used to study the effect of RF on the assay. Positive and negative control sera. A serum sample from a patient with serologically and clinically confirmed acute hepatitis B was used as a positive reference serum throughout the study. Serum from a healthy laboratory technician who was negative for serological markers of hepatitis B was used as a negative reference.
Quantitation of anti-HBcAg IgM antibody activity. The quantitation of antibody activity in samples was based on the use of positive and negative reference sera which were included in the assay. Antibody levels were expressed as arbitrary units, EIA units (EIU), which were determined by the formula (11) EIU, where OD is the optical density measured at a wavelength of 492 nm. The limit value for positivity was determined as the mean plus three standard deviations (SDs) of the antibody levels for the negative controls.
RESULTS
Biotin labeling of the antigen. HBsAg was allowed to react with different amounts of BNHS, and the preparations were tested with known anti-HBcAg IgM-positive and -negative reference sera (Fig. 1) . The highest positive:negative ratio was achieved when the ratio of BNHS to antigen was 1.5 (wt/wt). With this preparation, the negative reference serum gave reasonably low absorbance readings throughout the dilution range, whereas the positive reference still exceeded the. cutoff level at a dilution of 1:100,000, corresponding to a protein concentration of 20 ng/ml (Fig. 2) .
Determination of optimal conditions for the assay. We determined the optimal dilutions of the reagents and proper times and temperatures for incubations by varying each parameter individually while keeping the other variables constant. A dilution of 1:3,000 of rabbit anti-human IgM and incubation at +4°C overnight was optimal for coating of the solid phase. Dilutions of biotin-labeled HBcAg were tested with different dilutions of positive and negative reference sera (Fig. 3) . The highest positive:negative ratio with a linear E 2. A dilution of 1:1,000 for serum samples gave the highest specific reactivity. Incubation for 1 h at +37°C was optimal for both sample and antigen incubations. High specific reactivity with a low background was achieved with 30 min of incubation at +37°C for the ABC.
Application of the assay to clinical samples. First, 465 samples negative for other hepatitis B markers were studied. All of these sera were negative for anti-HBcAg IgM, with a mean antibody level of 2.1 EIU and an SD of 4.3 EIU. The limit value for positivity was thus determined as 15 EIU, corresponding to a limit of confidence of 99% (P < 0.01).
A clear correlation between the EIA antibody levels for anti-HBcAg IgM and the acuteness of disease was observed when 45 follow-up sera from 23 patients with acute or recent hepatitis B were tested (Fig. 4) . All of the sera collected during the first month after the onset of symptoms were positive for anti-HBcAg IgM, with a very high mean antibody level of 194 EIU and an SD of 27 EIU. A rapid decline in anti-HBcAg IgM levels was subsequently observed. A mean antibody level of 83 EIU with an SD of 30 EIU was detected in sera from the third month of the follow-up period. However, all of these sera were still positive although two of these five sera had already converted to HBsAg negative. Anti-HBcAg IgM disappeared, in most cases, 6 to 12 months after the onset of disease; a mean antibody level of 11 EIU with an SD of 15 EIU was detected. All of the six serum samples from that period were negative for HBsAg.
Sera from 20 chronic carriers on HBsAg were also tested for anti-HBcAg IgM. A mean antibody level of 10 EIU with an SD of 4 EIU was found. Two of these patients (10%) could be considered positive for anti-HBcAg IgM, although at very low antibody levels.
None of the 21 serum samples from patients with past hepatitis B was positive for anti-HBcAg IgM. The mean antibody level of 2.5 EIU with an SD of 5 EIU was very close to the mean antibody level for negative control sera.
We also tested 10 sera which were positive for anti- HBcAg and RF, as determined by a latex agglutination test, for anti-HBcAg IgM to assess the possible interfering effect of RF on the present assay. However, all of these sera were totally negative, with a mean antibody level of 2.3 EIU and an SD of 4 In other assays using capture enzyme immunoassay for the determination of virus-specific IgM antibodies, overnight incubation of the antigen has often been used (2, 4, 5, 7, 8) . In the present assay, only 1 h of incubation was needed for optimal reactivity, which might be explained by the small size of the biotin-antigen complex. Only Patients with past hepatitis B infection had essentially the same anti-HBcAg IgM antibody levels as negative controls, emphasizing the high specificity of the assay. Interestingly, chronic carriers of HBsAg did show slightly higher mean antibody levels than did controls. This difference was statistically significant (P < 0.001). However, even the highest antibody levels seen among carriers of HBsAg just exceeded the limit value for positivity.
It is hard to see why chronic carriers of HBsAg should have a continuous synthesis of IgM class antibodies against core antigen in a situation in which such antigen is not believed to be synthesized. One possible explanation for slightly elevated anti-HBcAg IgM activity would be a nonspecific reactivity, which could be mediated through the presence of HBsAg in these sera. However, further studies are needed to clarify this phenomenon.
The technique described seems to be sensitive and specific and has good clinical applicability. Excellent differentation among patients with acute and past hepatitis B as well as patients who are chronic carriers of HBsAg was achieved, suggesting that the determination of anti-HBcAg IgM could be used as one of the main indicators of acute hepatitis B infection.
